First National Bank of Omaha Purchases Shares of 148,230 Abbott Laboratories $ABT

First National Bank of Omaha purchased a new position in Abbott Laboratories (NYSE:ABT) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 148,230 shares of the healthcare product maker’s stock, valued at approximately $19,854,000. Abbott Laboratories accounts for 1.3% of First National Bank of Omaha’s investment portfolio, making the stock its 13th biggest position.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Trust Co lifted its position in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after acquiring an additional 15,394 shares in the last quarter. Asset Management One Co. Ltd. grew its position in shares of Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after purchasing an additional 19,966 shares in the last quarter. Nordea Investment Management AB raised its stake in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after purchasing an additional 18,974 shares during the period. AE Wealth Management LLC lifted its holdings in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares in the last quarter. Finally, iA Global Asset Management Inc. boosted its stake in Abbott Laboratories by 94.0% in the 3rd quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock worth $19,296,000 after purchasing an additional 69,803 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 0.4%

NYSE ABT opened at $112.27 on Wednesday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23. The firm has a market capitalization of $195.22 billion, a price-to-earnings ratio of 30.18, a PEG ratio of 1.79 and a beta of 0.75. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average of $119.12 and a two-hundred day moving average of $126.18.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ABT. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Evercore dropped their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Argus cut their price objective on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Finally, Citigroup decreased their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.